| |
PRZOOM - /newswire/ -
Arlington, VA, United States, 2008/06/20 - Until now, commercially available PARP assay kits required multiple steps and were time consuming. Trevigen overcomes these drawbacks with the release of the HT Fluorescent Homogeneous PARP Inhibition Assay.
|
| |
|
| |
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements
Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!
|
| |
Poly(ADP-ribose) polymerase, through ribosylation of nuclear proteins, converts DNA Damage into intracellular signals that actuate either DNA repair or cell death. The development of inhibitors to PARP is of ever increasing interest in the drug discovery community since they can be used as modulators of DNA repair mediated resistance to cytotoxic cancer therapeutics. Until now, commercially available PARP assay kits required multiple steps and were time consuming.
Trevigen overcomes these drawbacks with the release of the HT Fluorescent Homogeneous PARP Inhibition Assay. The fluorescent assay is based on the consumption of NAD+ in the PARP ribosylation reaction where NAD+ not consumed by PARP is subsequently measured by a cycling reaction in which a highly fluorescent molecule is produced; therefore an increase in signal positively correlates to increased PARP inhibition. The subject of a Trevigen patent application, it is a simple assay requiring only 1.5 hours from start to finish. The 96 test assay requires no wash steps, and detects as little as 10% inhibition ofPARP Activity. The assay is ideal for the determination of IC50 values for PARP Inhibitors.
Trevigen, Inc. is a rapidly growing biotechnology company focused on the development of products and technology for cancer research, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. Trevigen has been a long-standing provider of quality reagents and kits for researchers investigating programmed cell death and DNA damage and repair. A logical extension of the focus on cancer research has been the recent development of assays for cancer cell function and behavior including angiogenesis, cell invasion and tumor formation. Currently, the product portfolio contains over 500 products categorized into four processes – Apoptosis, DNA Damage and Repair, Angiogenesis, and Oxidative Stress.
Related Products from Trevigen include PARP and PARG assay kits, PARP enzymes and PARP antibodies.
|
| |
 |
| |
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements
Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!
|
| |
Agency / Source: Trevigen, Inc.
|
| |
 |
| |
Availability: All Regions (Including Int'l)
|
| |
Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker
|
| |
Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]
|
| |
 |
| |
# # #
|
| |
|
| |
 |
| |
Your Banner Ad showing on ALL Research articles, CATCH Visitors via Your Competitors Announcements!
 Company website links NOT available to basic submissions |
|
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source. |
| |
 |
| |
For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
PARP Inhibition Assay
| |
Contact: Belinda De Leon - Trevigen.com
1-800-873-8443 info[.]trevigen.com
|